Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLD1 | Q13393 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | F9 | P00740 | 1/20 | 0.30 |
| ▸ | F10 | P00742 | 1/20 | 0.30 |
| ▸ | F12 | P00748 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | F7 | P08709 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21124325 | 1.00 | PLD1 (0.36) | PLD1DPP4SIGMAR1F2F9 | |
| SCHEMBL18096136 | 0.80 | DPP4 (0.38) | PLD1DPP4SIGMAR1F2F9 | |
| SCHEMBL19806290 | 0.80 | SIGMAR1 (0.30) | SIGMAR1 | |
| SCHEMBL21036085 | 0.78 | SIGMAR1 (0.37) | SIGMAR1F2 | |
| SCHEMBL31591902 | 0.77 | HDAC8 (0.42) | PLD1 | |
| SCHEMBL27041826 | 0.75 | PLD1 (0.38) | PLD1DPP4 | |
| SCHEMBL20994238 | 0.73 | CYP3A4 (0.40) | PLD1 | |
| SCHEMBL21124129 | 0.73 | PLD1 (0.39) | PLD1DPP4SIGMAR1 | |
| SCHEMBL21124125 | 0.73 | PLD1 (0.39) | PLD1DPP4SIGMAR1 | |
| SCHEMBL20994235 | 0.73 | CYP3A4 (0.40) | PLD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3489231-B1 | PIPERAZINE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2021-06-09 | — | — | EP | disclosed |
| EP-3489231-A1 | PIPERAZINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2019-05-29 | — | — | EP | disclosed |